BARCELONAâ€”More pre-menopausal women who have estrogen receptor (ER) positive advanced breast cancer could be spared chemotherapyâ€”according to latest findings from the MONALEESA-7 double-blind randomized phase 3 trial in which either placebo (PBO) or the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (RIB) were added to tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with all patients also having ovarian suppression by goserelin therapy.
At the 2018 European Breast Cancer Conference (EBCC 11) Nadia Harbeck MD, Professor of Gynaecology and head of the Breast Center at the University of Munich in Germany said that following her groupâ€™s latest study findings practice should change for young, pre-menopausal patients who presented for the first time with hormone receptor positive human epidermal growth factor receptor2- (HER2)-negative advanced breast cancer. She discusses her findings with the Audio Journal of Oncology.
Emiel J T Rutgers MD PhD FRCS from the Netherlands Cancer Institute, Professor of Surgical Oncolology at the University of Amsterdam, who was not involved with the study, said the results were very interesting. â€œWe have now another possibility added to our armamentarium. My opinion is that in pre-menopausal women who recur with hormone-sensitive estrogen-dependent breast cancer with visceral or bony metastasis a re-challenge with anti-hormonal treatment including ribociclib or a comparable [agent] is now the first option. And the side-effect profile is rather mildâ€”so thatâ€™s another positive thing about it.â€
LATE BREAKING ABSTRACT 1LBA:
Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial